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Clostridium difficile is a toxin-producing bacterium that is a frequent cause of
hospital-acquired and antibiotic-associated diarrhea. The incidence, severity, and costs
associated with C. difficile associated disease are substantial and increasing, making
C. difficile a significant public health concern. The two primary toxins, TcdA and
TcdB, disrupt host cell function by inactivating small GTPases that regulate the actin
cytoskeleton. This review will discuss the role of these two toxins in pathogenesis and the
structural and molecular mechanisms by which they intoxicate cells. A focus will be placed
on recent publications highlighting mechanistic similarities and differences between TcdA,
TcdB, and different TcdB variants.
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CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE
Clostridium difficile was first described in 1935 by Ivan Hall
and Elizabeth O’Toole (Hall and O’Toole, 1935). The researchers
discovered the bacteria while investigating the bacterial coloniza-
tion of the intestinal tracts of normal infants during the first
10 days following birth. Hall and O’Toole found that C. difficile
was toxic toward animals and produced secreted toxic factor(s).
Nevertheless, the bacteria had been isolated from normal infants,
and there was no indication that the presence of the bacte-
ria had any deleterious effects on the newborns. Thus, for the
next four decades C. difficile remained a little known bacterium
that was considered a part of the normal intestinal flora of
infants.
C. difficile’s rise from obscurity began in the 1970s when it
was found to be the primary cause of pseudomembranous colitis
(PMC). PMC is a severe condition characterized by inflammation
of the colonwith the formation of plaques, or pseudomembranes,
composed of fibrin, mucin, necrotic epithelial cells, and neu-
trophils. (Lyerly et al., 1988; Kelly et al., 1994). PMC had been
described as early as 1893, but the causative agent was unde-
fined for decades (Finney, 1893). Following the development and
use of broad-spectrum antibiotics, the number of PMC cases
increased dramatically (Lyerly et al., 1988). An especially large
number of reported cases occurred in the 1970s following intro-
duction of clindamycin (Cohen et al., 1973; Kabins and Spira,
1975). With this rise in incidence, the search for the cause of
PMC intensified, and by the late 1970s there was strong evi-
dence from a number of groups that C. difficile was the causative
agent (Lyerly et al., 1988). Moreover, the toxic secreted compo-
nents that Hall and O’Toole noted in filtrates from C. difficile
cultures were implicated in causing PMC. The toxic components
were identified as two proteins, toxin A (TcdA) and toxin
B (TcdB).
Although the pathogenicity of C. difficile toward humans was
first discovered in relation to its ability to cause PMC, it is now
known that the manifestations of C. difficile infection can range
from asymptomatic carriage, to mild diarrhea, to life-threatening
conditions such as PMC and toxic megacolon. Collectively, the
manifestations of disease caused by C. difficile are referred to as
C. difficile associated disease (CDAD). Sohn et al. have estimated
that there are 7 CDAD case patients per 1,000 admissions in acute
care hospitals (Sohn et al., 2005). It should be noted, however,
that C. difficile burden varies dramatically by geographic region,
between institutions, and even between wards of the same hospi-
tal (Lyerly et al., 1988; Bartlett, 1994; Sohn et al., 2005; McDonald
et al., 2007). Total costs of C. difficile to the US health care sys-
tem are thought to exceed $3 billion per year (Kyne et al., 2002;
Brazier, 2008).
Between the late 1990s and mid 2000s there was a dramatic
increase in the number of cases of CDAD. Rates of CDAD
more than doubled in many localities (Kelly and LaMont, 2008).
According to death certificate data,C. difficile related deaths in the
US rose from 5.7 deaths per million in the population in 1999 to
23.7 in 2004 (Redelings et al., 2007). This vast upsurge in CDAD
has been primarily attributed to the emergence of more virulent
strains categorized as North American pulsotype 1/PCR-ribotype
027 (NAP1/027). NAP1/027 strains have been reported to have
higher production of TcdA and TcdB (Warny et al., 2005), a more
cytopathic form of TcdB (Stabler et al., 2008; Lanis et al., 2010),
production of binary toxin (McDonald et al., 2005), higher rates
of sporulation (Merrigan et al., 2003; Akerlund et al., 2008), and
increased antibiotic resistance (McDonald et al., 2005).
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VIRULENCE FACTORS OF C. DIFFICILE
Several factors have been implicated in the virulence of C. dif-
ficile including adhesins (Waligora et al., 2001), extracellular
enzymes (Savariau-Lacomme et al., 2003), fimbrae (Borriello
et al., 1990), flagella (Delmee et al., 1990; Stabler et al., 2006),
capsule (Borriello et al., 1990), and a paracrystalline S-layer
(Karjalainen et al., 2001; Sebaihia et al., 2006). In addition,
C. difficile produces three secreted protein toxins: TcdA, TcdB,
and the binary toxin CDTab. CDTab is an actin-specific ADP-
ribosyltransferase that is homologous to iota toxin from C. per-
fringens (Popoff et al., 1988; Perelle et al., 1997). Many pathogenic
strains do not produce CDTab (Rupnik et al., 2003), and the role
of binary toxin in pathogenesis is unclear (Perelle et al., 1997;
Barbut et al., 2005; Geric et al., 2006).
TcdA and TcdB are 308 and 270 kDa proteins, respectively,
with 49% identity and 63% similarity. They belong to a larger
family of large clostridial toxins (LCTs) which includes lethal and
hemorrhagic toxins from C. sordellii (TcsL and TcsH), α-toxin
from C. novyi (Tcnα), and large cytotoxin from C. perfringens
(TpeL) (Table 1). LCTs are homologous toxins that inactivate
host Rho and Ras family guanosine triphosphatases (GTPase) by
glucosylation. The Rho and Ras family GTPases are master reg-
ulators of a number of vital cellular processes including cycle
progression, cell-cell adhesion, cytokinesis, secretion, and main-
tenance of the cytoskeleton (Bishop and Hall, 2000; Jank et al.,
2007b).
ROLES OF TcdA AND TcdB IN VIVO
EFFECTS OF THE TOXINS ON CELLS
The most obvious change in cells treated with TcdA or TcdB is
the loss of cytoskeletal structure. Both toxins induce rounding in
a wide range of cell types. Although TcdA and TcdB have the same
general mechanism of action, they have several phenotypic differ-
ences. In the capacity to round cells, TcdB is 100–10,000 times
more potent than TcdA in many cell types (Donta et al., 1982;
Tucker et al., 1990; Aktories, 1997; Chaves-Olarte et al., 1997).
TcdA and TcdB also cause cells to die. Cell death and cell-
rounding are distinct events in intoxication (Qa’Dan et al.,
Table 1 | Large clostridial toxins.
Toxin Species Mol. weight Lethal Targets
activity1
TcdA difficile 308 kDa 50 ng Rho, Rac, Cdc42, Rap
TcdB difficile 270 kDa 50 ng Rho, Rac, Cdc42
TcdB-F2 difficile 270 kDa 50 ng Rac, Ras, Ral, Rap
TcsH sordellii ∼300 kDa3 75 ng Rho, Rac, Cdc42
TcsL sordellii 270 kDa 5 ng Rac, Ras, Ral, Rap
Tcnα novyi 250 kDa 5–10 ng Rho, Rac, Cdc42
TpeL perfringens 191kDa 16μg Rac, Ras, Ral, Rap
1 Amounts listed are for one mouse lethal dose and were obtained by intraperi-
toneal injection (Ball et al., 1993; Amimoto et al., 2007).
2 TcdB-F is a variant TcdB produced by the TcdA−TcdB+ strain 1470 (Chaves-
Olarte et al., 1999).
3 The amino acid sequence for TcsH is unknown. The estimated molecular
weight is based on SDS-PAGE (Martinez and Wilkins, 1988).
2002). To distinguish between the two events, cell-rounding and
cell death are sometimes referred to as the cytopathic effect
and cytotoxic effect, respectively. TcdA and TcdB have been
reported to cause death through a number of different mecha-
nisms including p53-dependent and p53-independent apoptosis,
caspase-dependent and caspase-independent apoptosis, as well as
necrosis (Warny and Kelly, 1999; Hippenstiel et al., 2002; Qa’Dan
et al., 2002; Kim et al., 2005; Matarrese et al., 2007; Nottrott et al.,
2007).
TcdA and TcdB have a number of effects on cells that do not
necessarily result in rounding or death, yet may contribute to
pathogenesis. Inactivation of Rho GTPases by TcdA and TcdB
results in the disruption of cell-cell junctions, which may con-
tribute to the increased epithelial permeability and lumenal fluid
accumulation associated with CDAD (Feltis et al., 2000; Johal
et al., 2004). Both toxins also induce the secretion of cytokines
in epithelial and immune cells. These include tumor necrosis fac-
tor, IL-1, IL-6, and IL-8 (Savidge et al., 2003). IL-8, in particular,
is thought to play a pivotal role in C. difficile pathogenesis. IL-
8 is involved in the recruitment and activation of neutrophils,
which are present in high amounts at sites of C. difficile associ-
ated inflammation. A polymorphism in the IL-8 gene has been
associated with susceptibility to recurrent CDAD (Jiang et al.,
2006).
EFFECTS OF THE TOXINS IN ANIMALS
The activities of purified TcdA and TcdB have been investigated
in a number of animal models including mice, rats, rabbits, and
hamsters. Although the manifestations of disease vary in the dif-
ferent animals, in these models TcdA induces fluid accumulation
and inflammation within the intestinal tract, whereas TcdB causes
minimal or no intestinal pathology (Lyerly et al., 1982, 1985;
Mitchell et al., 1986). In the rabbit ligated ileal loops, for exam-
ple, TcdA induces fluid accumulation with comparable activity
to cholera toxin (Lyerly et al., 1982). Unlike cholera toxin, the
toxin also causes extensive tissue damage and the accumulated
fluid is hemorrhagic (Lyerly et al., 1982, 1988). TcdB has no
effect in this assay. Likewise, when TcdA and TcdB are given to
mice and hamsters intragastrically, TcdA causes intestinal hem-
orrhage, diarrhea, and death, but TcdB has no effect (Lyerly et al.,
1985). TcdB, is however, a potent toxin toward these animals
when administered by other routes. When given by intraperi-
toneal injection, TcdA and TcdB are both lethal toxins with
similar potencies (Table 1) (Ball et al., 1993).
Based on these early studies, TcdA was referred to as the
enterotoxin, and TcdB, because of its ∼1000-fold higher cyto-
pathic potency toward cultured cells, was referred to as the
cytotoxin. It was proposed that TcdA induced the initial damage
in the colonwhere TcdB alone was relatively inert. After TcdA had
disrupted the intestinal epithelium, TcdB might then access and
act on other tissues (Lyerly et al., 1988). This model implicated
TcdA as the key virulence factor in disease and TcdB as, perhaps,
an accessory virulence factor. In support of this model, Lyerly
et al. showed that if TcdB is given to hamsters with damaged
intestines or together with sublethal doses of TcdA the animals
die. Furthermore, a humoral immune response against TcdA
correlates with protection from disease both in humans and in
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animal models (Warny et al., 1994; Kyne et al., 2001; Giannasca
and Warny, 2004; Babcock et al., 2006).
More recently, a number of pieces of evidence have shown
TcdB has a much more important role in disease than pre-
viously appreciated. Since the 1990s, a number of pathogenic
strains have been identified that produce TcdB, but not TcdA.
These TcdA−TcdB+ strains cause the same range of symptoms
as TcdA+TcdB+ strains in humans, and are pathogenic in ani-
mal models (Sambol et al., 2000). Thus TcdA is not essential
for pathogenesis. To date, no pathogenic TcdA+TcdB− clini-
cal isolates have been identified. In addition, there have been
reports that while TcdB may not be enterotoxic in animal mod-
els, it is toxic toward human colonic tissues. Riegler et al. tested
the effects of TcdA and TcdB on human colonic explants and
found that TcdB was ∼10 times more potent than TcdA at dis-
rupting the integrity of the membrane (Riegler et al., 1995).
Savidge et al. have demonstrated the toxicity of TcdB in a chimeric
mouse model of disease where a human fetal intestinal xenograft
is transplanted into an immunodeficient mouse (Savidge et al.,
2003). When challenged with either TcdA or TcdB, the human
xenografts exhibited intestinal epithelial cell damage with marked
necrosis, increased mucosal permeability, and acute mucosal
inflammation.
Elucidating the roles of TcdA and TcdB in pathogenesis has
been slow, partially due to the lack of genetic tools for the manip-
ulation of C. difficile (O’Connor et al., 2006). In 2009, Lyras
et al. reported results from animal infections conducted with tcdA
and tcdB mutants (Lyras et al., 2009). Clindamycin-treated ham-
sters were challenged with isogenic strains lacking either toxin.
Surprisingly, knocking out TcdA seemed to have no effect on the
virulence of the strain. Strains lacking TcdB, however, were avir-
ulent. Death of the hamster was the only reported phenotype, so
it is not clear if the TcdA+TcdB− strains had subtler pathological
effects. In similar experiments carried out by Kuehne et al., TcdA
and TcdB deficient mutants were both shown to have pathologic
effects in hamsters (Kuehne et al., 2010). Efforts to further evalu-
ate the roles of toxin in the context of mouse infection models are
on-going (Chen et al., 2008).
Although TcdA and TcdB have long been accepted as the pri-
mary virulence factors of C. difficile, it is clear that the two toxins
have distinctive properties both in animals and on cells. In addi-
tion, several isoforms of TcdB have been noted. TcdB from the
NAP1/027 strain R20291 is >1000-fold more cytopathic than
TcdB from the prototypical 630 strain on a number of cell lines
(Stabler et al., 2009). TcdA−TcdB+ strains (e.g., 1470 and 8864)
produce variant forms of TcdB that have altered substrate speci-
ficity. Understanding the molecular roles of TcdA, TcdB, and
variant toxins in pathogenesis is important for the development
of therapeutic strategies aimed at disrupting the action of these
toxins.
TcdA AND TcdB STRUCTURE ANDMECHANISM OF ACTION
TcdA and TcdB are homologous AB toxins. They can be divided
into two components: an enzymatic A subunit and a B subunit
involved in the delivery of the A subunit into the target cell
(Figure 1). The A subunit is an N-terminal glucosyltransferase
domain (GTD) that inactivates host GTPases by glucosylation.
Three additional domains within the B component are respon-
sible for delivery of the GTD to the cytosol of the host cell. These
include a receptor-binding domain, a “delivery” or pore-forming
domain, and an autoprotease domain. The mechanism of action
can be divided into four steps that are mediated by the four
known domains: (1) binding/internalization, (2) pore-formation
and translocation of the GTD across the membrane, (3) release of
the GTD by autoproteolysis, and (4) inactivation of host GTPases
by glucosylation (Figure 1B). The four main steps of intoxication
are discussed below.
RECEPTOR-BINDING
The C-termini of TcdA and TcdB consist of highly repetitive
structures termed combined repetitive oligopeptides (CROPs)
which are contained within amino acids 1832–2710 and 1834–
2366, respectively (von Eichel-Streiber and Sauerborn, 1990; Ho
et al., 2005). The CROPs are made up of multiple 19–24 amino
acid short repeats (SRs) and 31 amino acid long repeats (LRs)
(von Eichel-Streiber and Sauerborn, 1990; Jank et al., 2007b).
The TcdA CROPs domain comprises 32 SRs and 7 interspersed
LRs (Figure 2A). The domain in TcdB is considerably shorter and
contains 19 SRs and 4 LRs. Together the LR and SRs form cell wall
binding motifs that bind sugar moieties on the surface of host
cells (von Eichel-Streiber et al., 1992a,b). Cell wall binding motifs
from TcdA were initially shown to bind α-Gal-(1,3)-β-Gal-(1,4)-
β-GlcNAc (Krivan et al., 1986). However, this sugar is not present
on human cells (Tucker and Wilkins, 1991). TcdA has since been
reported to bind to the human I, X, and Y blood antigens as well
as a human glycosphingolipid which all have a core β-Gal-(1,4)-
β-GlcNAc structure (Tucker and Wilkins, 1991; Teneberg et al.,
1996). It is not known which of these, if any, serve as the native
ligand in the human colon.
Two proteins have been implicated as receptors for TcdA.
Rabbit sucrose-isomaltase was first shown to serve as a receptor
for TcdA in the rabbit ileum (Pothoulakis et al., 1996). Binding
to sucrose-isomaltase was inhibited by galactosidase treatment,
indicating that the toxin binds glycosyl modification(s) on the
protein, but the identity of the sugar(s) is unknown (Pothoulakis
et al., 1996). Rabbit sucrose-isomaltase cannot be the only recep-
tor for TcdA, becausemany cells and tissues, including the human
colonic epithelium, do not express this protein yet are sensitive
to TcdA (Pothoulakis et al., 1996). More recently, human gp96
has been reported as a receptor for TcdA (Na et al., 2008). Like
sucrose-isomaltase, gp96 is predicted to be glycosylated, but the
identities of the saccharides have not been determined. It has not
been shown for gp96 whether or not the saccharide modifications
are involved in binding TcdA. No receptors have been described
for TcdB.
In 2005, Ho et al. published the crystal structure of a fragment
of TcdA comprising amino acids 2573–2709 (TcdA CROPs f1)
[pdb 2F6E (Ho et al., 2005)]. This fragment contains 4 SRs and
1 LR. The structure revealed that each repeating element consists
of a β-hairpin followed by a loop. In the SRs, the loops are 7–
10 amino acids in length, whereas the LR loop contains 18 amino
acids. The SRs are packed together in a regular fashion where each
repeat is rotated by ∼120◦ in relation to the previous one (Ho
et al., 2005). The repetitive stacking of SRs forms straight, rod-like
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FIGURE 1 | TcdA and TcdB primary structure and mechanism of
cellular intoxication. (A) TcdA and TcdB are homologous AB toxins
consisting of four domains. The enzymatic A component is an N-terminal
glucosyltransferase domain (GTD) (red). The B component, involved in
delivery of the GTD into the cell, has three identified domains: combined
repetitive oligopeptides (CROPs) (green), “delivery” or pore-forming
(yellow), and autoprotease domains (blue). The orange box represents the
hydrophobic region of the delivery domain that has been proposed to form
part of the transmembrane pore (amino acids 956–1128 of TcdB). (B) The
delivery process is divided into four main steps that are mediated by each of
the four domains. (1) The toxin binds to the surface of the cell and is
internalized by receptor-mediated endocytosis. (2) Acidification of the
endosome triggers the formation of a pore through which the GTD is
translocated. (3) The GTD is released into the cytosol by InsP6 dependent
autoproteolysis. (4) The GTD glucosylates Rho family GTPases at the cell
membrane.
structures. The LR’s packing with its adjacent SRs disrupts the
regular repeating arrangement of the SRs, causing a ∼30◦ kink
in the rod-like structure (Ho et al., 2005). Using the structure of
the TcdA CROPs f1 as a template of SR-SR and SR-LR interac-
tions, Ho et al. constructed a model of the entire TcdA and TcdB
CROPs domains (Figure 2B).
The same group later published a co-crystal structure of a
larger fragment (f2) of the TcdA C-terminal repeats in com-
plex with an α-Gal-(1,3)-β-Gal-(1,4)-β-GlcNAc derivative [pdb
2G7C (Greco et al., 2006)]. This structure revealed that the sac-
charides bind at the junctions formed between LRs and SRs
(Figure 2C). Thus, each of the kinked regions in Figure 2B repre-
sents a putative saccharide binding side. TcdA has 7 such binding
sites, whereas TcdB has 4. The model taken from these structures
implies multivalent binding along an extended binding domain
(Greco et al., 2006).
The binding of α-Gal-(1,3)-β-Gal-(1,4)-β-GlcNAc is shown in
Figures 2C,E. The terminal α-Gal abuts the large loop of the LR
and makes several hydrogen-bonding contacts with residues of
the loop (e.g., Gln2638) (Figure 2D). The central β-Gal moiety
sits with its methoxy group pointed down into a small acidic
cleft formed in part by Glu2623. The oxygen of the methoxy
group hydrogen bonds with Lys2661 of the SR. The GlcNAc group
interacts with a number of SR residues including a hydrogen bond
formed with Ser2660. The residues pointed out here (Glu2623,
Gln2638, and Ser2660, Lys2661) are all strictly conserved in the
saccharide binding repeats of the TcdA CROPs. Yet, these residues
are strikingly different in the TcdB CROPs. Glu2623, for exam-
ple, which contributes to the small acidic pocket where the β-Gal
binds is replaced by a bulky, basic residue (lysine) in each of
the TcdB LRs. Thus, while the TcdB CROPs are predicted to
have a similar fold to the TcdA CROPs, the residues compris-
ing the TcdA-saccharide binding sites are radically different. This
provides a likely explanation for why TcdB does not bind the
β-Gal-(1,4)-β-GlcNAc with the affinity of TcdA.
In addition to differences between TcdA and TcdB, it is also
of note that the C-terminal repeats of TcdB from the prototyp-
ical 630 strain and TcdB from the hypervirulent R20291 strain
differ considerably. The CROPs from the two toxins are 88%
identical, with some of the individual repeats having less than
80% identity (Lanis et al., 2010). Interestingly, the TcdB vari-
ant from the TcdA−TcdB+ strain 8864 has CROPs similar to
the R20291 TcdB (97% identical); whereas, the variant from the
TcdA−TcdB+ strain 1470 resembles the prototypical strain (99%
identical). Most of the differences in sequence are in the SRs, and
the putative saccharide binding sites are largely conserved. It will
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FIGURE 2 | Structure of the CROPs domain. (A) The TcdA CROPs domain
is made up of 32 short repeats (SRs) with seven interspersed long repeats
(LRs), which are represented by green and blue boxes, respectively. The
TcdB CROPs domain consists of 19 SRs and 4 LRs. (B) Models of the TcdA
and TcdB C-terminal repeats were constructed based on the structure of
TcdA CROPs f1 (Ho et al., 2005). The models are colored as in (A).
(C) Carbohydrate recognition by the TcdA CROPs. The crystal
structure of TcdA CROPs f2 (amino acids 2456–2710) is shown with the SRs
colored green and LRs colored blue. The head-group of the bound
liposaccharide α-Gal-(1,3)-β-Gal-(1,4)-β-GlcNAcO(CH2 )8CO2CH3 is
shown in yellow. (D,E) A close-up view of the trisaccharide-binding
pocket formed by an LR and adjacent SR. The electrostatic surface
potential is shown with negatively charged surfaces in red and positively
charged surfaces in blue [transparent in (D) and opaque in (E)].
In (D) residues that make up the trisaccharide binding pocket are shown as
sticks, and hydrogen bonds are shown as dashed lines. The labeled residues
are strictly conserved in the saccharide-binding repeats of TcdA but are
divergent in TcdB.
Frontiers in Cellular and Infection Microbiology www.frontiersin.org March 2012 | Volume 2 | Article 28 | 5
Pruitt and Lacy Structure of C. difficile toxins
be of interest to investigate if and how these amino acid changes
impact cell binding.
There are a number of pieces of evidence that suggest that the
CROPs are not the only parts of the proteins involved in binding
to cells. The homologous toxin TpeL from C. perfringens lacks the
C-terminal repeats yet is still toxic, albeit much less potent than its
homologs (Table 1) (Amimoto et al., 2007). Moreover, it has been
shown that removing the CROPS from TcdA or TcdB attenuates
but does not eliminate cytopathicity suggesting the existence of an
additional binding activity outside carbohydrate-binding repeats
(Barroso et al., 1994; Genisyuerek et al., 2011; Olling et al., 2011).
This has been most thoroughly demonstrated for TcdA. TcdA
lacking amino acids 1875–2710, which contains two SRs and no
LRs (therefore, no saccharide binding sites), is able to intoxicate
HT29 and 3T3 with 5–10-fold less potency than full-length toxin
(Olling et al., 2011).
The additional binding activity may be encoded in the region
preceding the C-terminal repeats. While removal of the CROPs
of TcdB only partially reduces cytopathic potency, truncation to
1–1500 or 1–1529 completely attenuates cytopathicity (Barroso
et al., 1994; Genisyuerek et al., 2011). If the receptor-binding
domain from diphtheria toxin is attached to the truncated TcdB
1–1500, it regains its ability to intoxicate cells (Genisyuerek et al.,
2011).
PORE FORMATION
TcdA and TcdB enter the cell by clathrin-mediated endocyto-
sis (Papatheodorou et al., 2010). Once the toxins have been
internalized, the glucosyltransferase must be delivered across the
endosomal membrane. Endosomal acidification is thought to
induce structural changes in the delivery domain that expose
hydrophobic segments. These hydrophobic regions insert into the
host membrane forming a pore through which the glucosyltrans-
ferase domain can pass. This model, which was initially based on
analogy to other pore-forming AB toxins, is now supported by
several studies.
Qa’Dan et al. have shown that acidification causes structural
rearrangements in TcdB. The authors demonstrated that upon
reduction of pH to 4.0, TcdB exhibits differences in native tryp-
tophan fluorescence, protease susceptibility, and results in the
exposure of hydrophobic surfaces (Qa’Dan et al., 2000). Barth
et al. demonstrated that acidification, not only induces conforma-
tional changes, but also triggers pore formation. Chinese hamster
ovary (CHO) cells were preloaded with 86Rb+, and then treated
with TcdB. Under acidic conditions, 86Rb+ was released into
supernatant when TcdB was present, indicating that TcdB inserts
into the plasma membrane and forms ion channels. The authors
showed that TcdB can induce ion channels in artificial lipid
bilayers at low pH (Barth et al., 2001). Barth et al. and Qa’Dan
et al. demonstrated that these results are also applicable in the
natural intoxication of cells. Treatment of cells with pharmacolog-
ical inhibitors of endosomal acidification (e.g., bafilomycin A1)
retards the toxic effects of TcdB, presumably by inhibiting pore
formation (Qa’Dan et al., 2000; Barth et al., 2001).
Most studies on the pore-forming activity of theC. difficile tox-
ins have used TcdB from strain 630. TcdA has also been shown to
form channels in cells and in artificial bilayers (Giesemann et al.,
2006). However, TcdA requires cholesterol for pore-formation
whereas TcdB does not. TcdB from the NAP1/027 strain R20291
has been shown to enter cells more quickly and undergo pH-
dependent conformational change at a higher pH than TcdB from
strain 630 (Lanis et al., 2010). The molecular bases for these
differences are unknown.
Pore formation and translocation are thought to be mediated
by the central delivery domain (∼aa 801–1831). BLAST analysis
of the delivery domain reveals two distinct regions of homol-
ogy (Pruitt et al., 2010). We have termed these two regions D1
(∼801–1400) and D2 (∼1401–1831). Within D1, amino acids
∼956–1128 are particularly hydrophobic and have been hypothe-
sized to compose at least part of the transmembrane pore (von
Eichel-Streiber and Sauerborn, 1990; von Eichel-Streiber et al.,
1992a). Genisyuerek et al. have recently constructed a series of
TcdB truncations to delineate the region of the toxin responsible
for pore-formation (Genisyuerek et al., 2011). Proteins contain-
ing residues 1–990 and 830–2366 (or 830–1025) are capable
of forming membrane channels at low pH suggesting that the
amino acids 830–990 contain the minimal pore-forming region
(Genisyuerek et al., 2011).
Within this region, the authors identified two residues (Glu970
and Glu976) that are involved in pore-formation (Genisyuerek
et al., 2011). When both residues are mutated to lysine, the toxin
is reduced in its ability to form pores at low pH and in its cyto-
pathic potency. These residues may be involved in the pH sensing
mechanism. At low pH, these acidic residues might be neutral-
ized by protonation, which could facilitate their insertion into
the membrane. These residues are not strictly conserved among
LCTs, but most of the toxins do have acidic residues at these
positions. TcdA, for example, has aspartate residues Asp972 and
Asp978 which could play a similar role. The variant TcdB from
strain 8864 is an exception; the residue corresponding to Glu970
is a glycine. The pore-forming activity of this toxin has not been
studied.
The finding that amino acids 830–990 contains the minimal
pore-forming sequence raises the question of what roles the other
875 residues in the delivery domain play in intoxication. The C-
terminal part of the delivery domain (D2) may have a role in
binding to cells as suggested in the previous section. So far, very
little is known about the structure of the delivery domains of
TcdA or TcdB in either the soluble or membrane states. It is also
not known whether the toxins must oligomerize in order to form
a pore. Understanding the structural changes that allow TcdA or
TcdB to go from being soluble proteins to membrane pores is
an exciting structural problem important for understanding the
function of these proteins.
AUTOPROTEOLYSIS
LCTs are made and secreted as single polypeptide chains. It was
unknown for many years whether the toxin remained intact or if
the A component (GTD) was released into the cell as is typical for
other AB toxins. It was first shown in 2003 that TcdB is proteolyti-
cally processed and that only the N-terminal GTD is released into
the cytosol (Pfeifer et al., 2003). The cleavage site was localized
between Leu543 and Gly544, and it was revealed that cleavage was
mediated by a component of the target cell cytosol (Rupnik et al.,
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2005). It was thought that this proteolytic event was mediated by
a host protease (Rupnik et al., 2005).
When Reineke et al. tried to identify the host factor required
for cleavage of TcdB, they found that the host factor was not
a protein but an inositol-phosphate (Reineke et al., 2007). The
most active of the inositol-phosphates was inositol hexakisphos-
phate (InsP6) (Reineke et al., 2007). When mixed with purified
LCTs, InsP6 alone was enough to induce cleavage. Egerer et al.
confirmed that cleavage was stimulated by InsP6 and showed
that a cysteine protease domain (CPD) adjacent to the GTD is
responsible for cleavage (Egerer et al., 2007).
The CPD was identified based on its homology to a CPD that
had just been discovered in the RTX toxin from Vibrio cholerae
(Sheahan et al., 2007). As in the LCTs, the V. cholerae RTX
(VcRTx) toxin CPD facilitates the release of enzymatic moieties
into the target cell, and it is also activated by InsP6 (Prochazkova
and Satchell, 2008). Crystal structures of the VcRTx [pdb 3EEB,
3FZY (Lupardus et al., 2008; Prochazkova et al., 2009)], TcdA
[pdb 3HO6 (Pruitt et al., 2009)], and TcdB [pdb 3PEE (Puri
et al., 2010)] CPDs have revealed that these domains share a sim-
ilar structure and mechanism of InsP6-induced activation. The
domains have a central β-sheet flanked by a number of α-helices
(Figure 3). The CPDs from TcdA and TcdB are larger than that of
VcRTx, containing extended helical regions, an inserted β-strand,
and a C-terminal extension, but the core fold of the structures is
conserved (Lupardus et al., 2008; Pruitt et al., 2009). Three con-
served catalytic residues, cysteine, histidine, and aspartate, cluster
on the edge of the β-sheet (shown as orange sticks in Figure 3).
InsP6 is bound at a separate site on one face of the β-sheet in a
basic, lysine-rich pocket (Figure 3). The InsP6 binding pocket is
separated from the catalytic triad by a structure termed the β-flap
(Figure 3, β-flap colored purple).
The aspartate, histidine, and cysteine residues of the catalytic
site have been shown to be essential in the auto-proteolytic pro-
cessing of VcRTx (Sheahan et al., 2007), TcdA (Pruitt et al.,
2009), and TcdB (Sheahan et al., 2007). However, they do not
form a conventional catalytic triad arrangement wherein the his-
tidine forms a hydrogen bond with the cysteine making the
cysteine more nucleophilic. The cysteine and histidine residues
are, instead, separated by a large cleft. Rather than acting to
increase the nucleophilicity of the cysteine, His655may be impor-
tant for stabilizing the oxyanion intermediate or protonating the
leaving group (Prochazkova et al., 2009; Pruitt et al., 2009).
The discovery of the CPD in TcdA and TcdB presents a
potential new target for therapeutics inhibiting the toxins. Puri
et al. have developed a number of small molecule inhibitors
of TcdB that act by covalent modification of the catalytic cys-
teine (Puri et al., 2010). A crystal structure of the TcdB CPD
was determined bound to one of these compounds, acyl-Gly-
Ser-Leu-acyloxymethyl ketone (Ac-GSL-AOMK) (Figure 4) [pdb
3PA8 (Puri et al., 2010)]. Ac-GSL-AOMK is a mimic of the
native TcdB substrate (Gly-Ser-Leu↓Ser-Glu-Asp). The leucine
side chain of the inhibitor binds in a hydrophobic pocket imme-
diately adjacent to the catalytic site (Figure 4). The hydrophobic
residues involved in binding to the substrate are largely con-
served among LCTs and RTX CPDs, and all of these CPDs cleave
after a leucine. The crystal structure of an inactive VcRTX CPD
with the substrate bound reveals that this protease has a similar
mechanism of substrate binding [pdb 3FZY (Prochazkova et al.,
2009)].
The CPD structures were obtained in the presence of InsP6.
NMR, circular dichroism, and limited proteolysis of the TcdA
CPD suggests that the domain is folded in both apo- and
InsP6-bound proteins but that InsP6 binding confers stability
and induces significant structural change (Pruitt et al., 2009).
Recent work by Shen et al. has demonstrated that the TcdB
CPD exists in a dynamic equilibrium between active and inac-
tive states (Shen et al., 2011). InsP6 binding shifts the equilibrium
markedly toward the active conformation. Shen et al. show by
mutational analysis that the β-flap plays an important role in the
N
N
C
TcdA CPD
InsP6
Cys700Cys3568
His655
Asp589
His3519
Asp3469
TcdB CPDVcRTX CPD
C
InsP6
InsP6 N
C
Cys698
His653
Asp587
FIGURE 3 | Structures of the VcRTX, TcdA, and TcdB CPDs. The crystal
structures of the CPDs are shown as ribbon diagrams. InsP6 and the catalytic
residues are shown as sticks (red and orange, respectively). The β-flap,
shown in purple, separates the InsP6 binding pocket from the catalytic site.
The N-terminus (dark blue) wraps around the protein such that the N-terminal
cleavage site is near the catalytic residues.
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Cys698
His653Asp587
InsP6
β-flap
Leu
FIGURE 4 | Inhibition of the TcdB by covalent modification of the
active site. The TcdB CPD catalytic site is shown with the substrate mimic
acyl-Gly-Ser-Leu-acyloxymethyl ketone (Ac-GSL-AOMK) (green) bound.
Catalytic residues are shown in orange and InsP6 is shown in red. The
leucine side chain of the Ac-GSL-AOMK is bound in a hydrophobic substrate
binding pocket (blue).
allosteric activation mechanism by coupling the InsP6-binding
and catalytic sites.
Cleavage is not equivalent between TcdA and TcdB. TcdB
holotoxin is more sensitive than TcdA holotoxin to InsP6-
induced cleavage in in vitro reactions (Kreimeyer et al., 2011). The
basis for this difference is not readily apparent from the struc-
tures of the CPD domains from the two toxins. It is possible that
these differences in sensitivity to InsP6 are due to areas outside
the domain. In our observations, the TcdA holotoxin undergoes
processing much less efficiently than a small fragment contain-
ing the protease domain (510–809). Therefore, factors outside the
protease domain affect cleavage, possibly to prevent premature
processing.
Collectively, the aforementioned structural and biochemical
data have revealed that InsP6-mediated autoproteolysis is a con-
served mechanism used by diverse toxins to release their cargo
into eukaryotic cells. This novel autoprocessing mechanism is
reviewed in greater detail in (Shen, 2010a,b) and (Egerer and
Satchell, 2010).
GLUCOSYLTRANSFER
The N-termini of the LCTs contain a 63 kDa GTD which is
released into the cell and inactivates small GTPases. GTPases are
molecular switches that cycle between active GTP-bound and
inactive GDP-bound states. Upon binding GTP, GTPases undergo
a conformational change allowing them to interact with sev-
eral effector molecules (Bishop and Hall, 2000; Aktories and
Barbieri, 2005). The repertoire of effector molecules is extensive
and includes protein and lipid kinases, phosphatases, lipases, and
scaffolding proteins. The downstream signaling cascades induced
by activation of Rho family GTPases are principally involved
in the regulation of the cytoskeleton and processes requiring
cytoskeletal rearrangements.
TcdA and TcdB preferentially act on GDP-bound, membrane
associated Rho GTPases (Just et al., 1995; Genth et al., 1999).
Using UDP-glucose as a co-substrate, the toxins inactivate Rho
proteins by monoglucosylation of Thr37 (Thr35 of Rac and
Cdc42) (Aktories and Just, 1995; Just et al., 1995). Thr37 is located
in the switch I region which is important for binding effectors
and regulatory proteins (Genth et al., 1999; Aktories and Barbieri,
2005; Jank et al., 2007b). Glucosylated Rho GTPases are no longer
able to interact with regulatory molecules or many of its effec-
tors, and therefore, numerous downstream signaling pathways are
interrupted (Herrmann et al., 1998; Sehr et al., 1998; Genth et al.,
1999; Aktories and Barbieri, 2005; Jank et al., 2007b).
Based on in vitro experiments, TcdA and TcdB can target
RhoA, RhoB, RhoC, RhoG, Rac1, Cdc42, and TC10 (Jank et al.,
2007b; Genth et al., 2008). TcdA has been reported to modify the
additional substrates Rap1A and Rap2A which are more closely
related to Ras family proteins (Chaves-Olarte et al., 1997). TcsH
and Tcnα also target Rho family substrates (Table 1) (Genth et al.,
1996; Selzer et al., 1996). TcsL and TpeL, on the other hand,
act mostly on Ras family proteins such as H-Ras, Ral, and Rap
(Nagahama et al., 2011). They can target Rac but not Rho. Like
the Rho proteins, the Ras GTPases are involved in a large num-
ber of cellular signaling pathways. They have important roles in
the regulation of cell-cell junctions, cell proliferation, and survival
(Raaijmakers and Bos, 2009).
The TcdB variants produced by strains 1470, 8864, and C34
modify Ras family substrates (Chaves-Olarte et al., 1999; Mehlig
et al., 2001; Huelsenbeck et al., 2007). These toxins are some-
times referred to as functional hybrids because most of the TcdB
protein is the same as in prototypical strains, but the GTD
modifies the same substrates as TcsL. Interestingly, all of the
TcdA−TcdB+ strains that have been characterized so far carry
these variant toxins. It is not known why some toxins preferen-
tially target Rho family proteins while others target Ras family
proteins, but it is clear that the inactivation of these different
proteins has different effects on cells (Giry et al., 1995; Chaves-
Olarte et al., 1999; Mehlig et al., 2001; Huelsenbeck et al., 2007).
TcsL and variant TcdBs which modify Ras family proteins cause
cells to have a spindle-like appearance (S-type cytopathic effect),
whereas treatment with TcdA and prototypical TcdB results in
an arborized appearance (D-type cytopathic effect) (Torres, 1991;
von Eichel-Streiber et al., 1995; Mehlig et al., 2001).
In 2005, Reinert et al. determined the crystal structure of the
TcdB GTD in complex with UDP-glucose [pdb 2BVM (Reinert
et al., 2005)]. The structures of the GTDs from three other
LCTs, TcdA, TcsL, and Tcnα, have also been determined [pdb
3SS1/3SRZ (Pruitt et al., 2012), 2VKD/2VKH, and 2VK9 (Ziegler
et al., 2008)]. These structures coupled with biochemical data
have shed light on the enzymatic mechanism of glucosyltrans-
fer. The structure of the TcdB GTD is presented in Figure 5. At
the core of the structure is a Rossman fold similar to what is
seen in other glycosyltransferases belonging to the glycosyltrans-
ferase A (GT-A) family (Reinert et al., 2005). In addition to the
common GT-A family fold, TcdB has a number of α-helical addi-
tions (red). These include anN-terminal 90-residue subdomain at
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N
FIGURE 5 | Structure of the TcdB glucosyltransferase domain. (A) The
core GT-A fold is shown in orange, and the α-helical additions are shown in
red. The N-terminal four-helix bundle makes up the MLD. (B) Close up view
of the catalytic core. UDP, glucose, and a manganese ion are bound on the
surface of the core GT-A fold. The binding pocket is overlayed by a loop
comprising residues 517–523. Some of the residues involved in
coordinating UDP, Glucose, and Mn2+ are shown as sticks. (C) Surface view
of the TcdB GTD as shown in (A). Glu449, Arg455, Asp461, Lys463, and
Glu472, residues that have been shown to be involved in GTPase binding, are
colored cyan.
the “bottom” of the GTD, as presented in Figure 5A, and several
other large protuberances at the “top right” and “top left.” The N-
terminal subdomain has recently been shown to target the GTD
to the plasma membrane, the site of the target GTPases (Mesmin
et al., 2004; Geissler et al., 2010). This region is, therefore, referred
to as the membrane localization domain (MLD). The role of the
other α-helical additions is unknown, but it has been suggested
that these residues are involved in substrate binding (Reinert et al.,
2005).
The structure of the TcdB GTD facilitated the identification of
important residues in the reaction mechanism. The α-anomeric
conformation of the glucose is retained in the glucosyltransfer
reaction (Vetter et al., 2000), and is thus thought to proceed
through a carboxonium intermediate (Ziegler et al., 2008). In the
TcdB GTD structure, UDP-glucose is hydrolyzed into UDP and
glucose, but both molecules are bound along with the cofactor
Mn2+ (Ciesla and Bobak, 1998; Reinert et al., 2005). As in other
GT-A proteins, UDP-glucose is bound in a pocket formed by the
edge of the β-sheet and several α-helices. A loop consisting of
residues 517–523 overlays the binding pocket, and two residues
within this loop (Ser518 and Trp520) are involved in binding the
phosphate group of UDP (Figure 5B). Figure 5B shows several
other key residues that are involved in binding UDP-glucose. The
activity of the enzyme is reduced or abolished when any of these
residues are mutated (Hofmann et al., 1997; Jank et al., 2007a).
The structure of the TcdB GTD was used as a platform to dis-
cover residues that are involved in binding target GTPases. Jank
et al. have found 5 residues (Glu449, Arg455, Asp461, Lys463,
and Glu472) that when mutated result in loss of substrate modifi-
cation. These residues are located adjacent to the UDP-glucose
binding pocket (cyan in Figure 5C). The transferred glucose is
only accessible from this “front” view of the GTD, thus the
GTPases must bind to this side of the molecule.
Our lab has recently determined the structure of the TcdA
GTD (Pruitt et al., 2012). The overall fold and UDP-glucose bind-
ing core of the TcdA and TcdB GTDs are similar, but the surfaces
of the two domains are very different (Figure 6). These differ-
ences are particularly striking on the proposed GTPase binding
surface. Differences on this surface are likely responsible for dif-
ferential substrate specificities. Notably, the residues which have
been shown to be involved in binding of TcdB to substrates
(Figure 5C, cyan) are not conserved among the LCTs. This is also
evident when examining TcdB from different strains. TcdB from
the prototypical strain 630 and the NAP1/027 R20291 have con-
served residues on the substrate binding surfaces. Isoforms from
the TcdA−TcdB+ strains 8864 and 1470, as well as TcdB from
strain C34, have accumulated a large number of mutations on
the substrate-binding surface relative to the TcdB from strain
630 (Figure 7) (Reinert et al., 2005). In 1470, 8864, and C34
TcdB the toxins have altered substrate recognition, targeting Ras
GTPases in addition to Rho family proteins. These GTD variants
are typically found in strains lacking TcdA, and may have arisen
to compensate for the loss of TcdA, which can modify at least a
subset of Ras family proteins (Rap2A).
HOLOTOXIN STRUCTURE
The structures of the individual domains of TcdA and TcdB
have provided considerable insight into the processes of receptor-
binding, autoprocessing, and enzymatic inactivation of host
GTPases. A structure of the delivery domain would be of consid-
erable interest, as pore-formation and translocation of the GTD
are poorly understood steps of the toxin mechanism. However, a
complete understanding of toxin function will require an under-
standing of how these domains interact with each other in the
context of the holotoxin. Low resolution maps of the holotoxins
have been determined by small angle X-ray scattering (SAXS) and
negative stain electron microscopy (EM). The SAXS study was
carried out on TcdB and revealed a modular structure into which
a structure of the TcdB GTD and models of the CPD and CROPs
domain could be placed (Albesa-Jove et al., 2010).
We have used negative stain EM to determine a 25 Å resolu-
tion structure of TcdA (Pruitt et al., 2010). The EM structure
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FIGURE 6 | The GTPase binding surfaces of the LCTs are
diverse. The electrostatic surface potentials of the GTDs of TcdA,
TcdB, TcsL, and Tcnα are shown with basic surfaces in blue and
acidic surfaces in red. These varied surfaces likely influence substrate
binding specificity. The in vitro substrates are listed below
each GTD.
FIGURE 7 | Variation of the substrate binding surface of TcdB from
different strains. Sequences of TcdB from strains 630, R20291, 1470,
8864, and C34 were aligned. The homology score for each residue was
mapped onto the surface of the TcdB GTD using ESPript and PyMOL
(Gouet et al., 1999). Strictly conserved residues are shown in red; divergent
residues are shown in blue.
reveals a bi-lobed structure from which there are two protrusions,
one long, and curved and the other shorter and wider. Within
this map we were able to experimentally localize three of the
four domains (Figure 8). The bi-lobed structure comprises the
delivery domain. These two lobes may make up the two delivery
subdomains, D1 and D2. The shorter of the protrusions repre-
sents the GTD, and the long curved protrusion corresponds to
the C-terminal repeats, and is consistent with the model of the
CROPs domain proposed by Ho et al. (2005).
The structure of TcdA described above represents a single
state of the protein. However, these toxins undergo a number
of conformational changes in response to environmental signals
during cellular intoxication. To begin investigating changes that
the toxin must undergo to insert into the membrane and form a
pore, we have also determined a structure of TcdA on the EM
grid following exposure to low pH (Pruitt et al., 2010). Upon
exposure to low pH, there are major changes within the delivery
FIGURE 8 | Domain organization of TcdA at neutral and low pH. EM
structures are colored by functional domain. GTD, red; CPD, blue; delivery
domain, yellow; CROPs, green. The dashed line represents possible
unfolding of the TcdA GTD N-terminus at low pH.
and glucosyltransferase domains (Figure 8). The delivery domain
takes on a more elongated shape as opposed to the bi-lobed
structure. This may reflect a change necessary for exposure of
hydrophobic residues that would insert into themembrane. There
is also a notable loss of density for the GTD.We suggest that this is
due to an unfolding of the GTD at low pH, which would facilitate
its translocation through the pore.
These structures have provided and initial map of the organi-
zation of the holotoxin. They are limited however, by their low
resolution. A combination of structural approaches will likely
be necessary to refine this model and understand the structural
changes that the toxins must undergo to accomplish the complex
task of cargo delivery.
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QUESTIONS FOR FUTURE STUDY
As the primary virulence factors of C. difficile, TcdA and TcdB
are prime therapeutic targets for treatment of CDAD. Still, many
questions remain regarding how the toxins deliver their cyto-
pathic cargo into target cells. What are the receptors for TcdA and
TcdB, and what cells do they target in vivo? Does D2 have a role
in binding to host cells? What is the nature of the pore structure
of the toxins? What structural rearrangements are necessary for
the toxins to access this pore state? How is the GTD translocated
through this pore? How is the autoprotease activity occluded in
the holotoxin, and when/how does it become activated?
There is also much to be learned about substrate modification
in cells. It is not clear how the GTDs bind their substrates and
how the distinct surfaces drive specificity for the target GTPases.
Most of what we know about toxin substrate specificity is from in
vitro experiments. Membrane localization and host factors likely
play an important role in determining what substrates are modi-
fied in vivo, so the array of actual targets may be different. Finally,
the consequences of modifying different subsets of GTPases for
pathogenesis are not known. Clearly, a great deal of work needs
to be done to understand the action of these toxins. Elucidating
the answers to these questions will help uncover the different roles
of TcdA, TcdB, and variant toxins and aid in the development of
strategies to prevent their action.
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